Skip to main content

Market Overview

The Week Ahead In Biotech: ASCO Presentations In The Spotlight

The Week Ahead In Biotech: ASCO Presentations In The Spotlight

Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector.

Surface Oncology Inc (NASDAQ: SURF) was one of the biggest advancers of the week after it announced an oncology partnership with Merck & Co., Inc. (NYSE: MRK).

Sorrento Therapeutics Inc (NASDAQ: SRNE), which announced on May 15 the discovery of 100%  inhibition of SARS-CoV-2, was in the news yet again this week as short sellers clamped down on the biotech, questioning the veracity of its claims.

AstraZeneca plc (NYSE: AZN) and Merck received the FDA nod for Lynparza to treat metastatic castration-resistant prostate cancer with homologous recombination repair mutations.

The following are key catalysts for the unfolding week:


2020 International Society of Cell and Gene Therapy, or ISCT, annual meeting: May 28-29.
American Society of Clinical Oncologists 2020 Virtual Scientific Program: May 29-31. 
American Society for Clinical Pathology, or ASCP, 2020 Annual Meeting (virtual conference): May 29-30. 


Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) await the FDA verdict on their sBLA for Dupixent in pediatric eczema. (Tuesday)

Clinical Readouts

Mersana Therapeutics Inc (NASDAQ: MRSN) will present interim data from the ongoing XMT-1536 Phase 1 dose expansion in patients with ovarian cancer and non-small cell lung adenocarcinoma.

See also: These 6 Coronavirus Vaccine Candidates Are The Likeliest To Succeed, Says Morgan Stanley

ASCO Presentations


  • Arvinas Inc (NASDAQ: ARVN): additional Phase 1 data on ARV-110 in castration-resistant prostate cancer
  • Trillium Therapeutics Inc (NASDAQ: TRIL): updated Phase 1a/b data on TTI-622 in refractory lymphoma or multiple myeloma
  • Cardiff Oncology Inc (NASDAQ: CRDF): Phase 1b/2 data on onvansertib, folfiri and avastin in KRAS-mutated colorectal cancer
  • Iovance Biotherapeutics Inc (NASDAQ: IOVA): new interim Phase 2 data on LN-144-lifileucel in refractory metastatic melanoma
  • Blueprint Medicines Corp (NASDAQ: BPMC): updated Phase 1/2 data for praksetinib in RET-altered tumors
  • Allogene Therapeutics Inc (NASDAQ: ALLO): Initial Phase 1 data for ALLO-501 in non-Hodgkin lymphoma
  • Deciphera Pharmaceuticals Inc (NASDAQ: DCPH): Phase 1b/2 data on rebastinib and paclitaxel in solid tumors
  • GENMAB A/S/S ADR (NASDAQ: GMAB): Phase 1/2 data on epcoritamab in B-cell lymphoma
  • AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO): Phase 3 data for tivozanib in third-line treatment of patients with renal cell cancer
  • Merck: Phase 3 data for Keytruda in colorectal cancer
  • Amgen, Inc. (NASDAQ: AMGN): updated Phase 1 data for AMG 510 in solid tumors
  • IMMUTEP LTD/S ADR (NASDAQ: IMMP): initial Phase 2 data for eftilagimod alpha and Keytruda in non-small cell lung cancer, head and neck cancer
  • Heat Biologics Inc (NASDAQ: HTBX): Phase 2 data on HS-110 and Opdivo in non-small cell lung cancer
  • Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL): updated Phase 2 data for AUTO3 in relapsed or refractory diffuse large B-cell lymphoma
  • Oncolytics Biotech, Inc. (NASDAQ: ONCY): interim Phase 1 data for pelareorep and carfilzomib/dexamethasone in multiple myeloma; interim Phase 2 data for pelareorep with Keytruda in pancreatic cancer
  • Athenex Inc (NASDAQ: ATNX): Phase 2 data on oraxol in angiosarcoma
  • Harpoon Therapeutics Inc (NASDAQ: HARP): preliminary Phase 1 data on HPN424 in metastatic castration-resistant prostate cancer
  • Gossamer Bio Inc (NASDAQ: GOSS): initial Phase 1/2 data on GB1275 in solid tumors
  • ImmunoGen, Inc (NASDAQ: IMGN): initial Phase 1b/2 data for mirvetuximab soravtansine in ovarian cancer and relapsed endometrial cancer
  • Merus NV (NASDAQ: MRUS): Phase 2 data for MCLA-128 in breast cancer
  • CytomX Therapeutics Inc (NASDAQ: CTMX): Phase 1 data for CX-2029 in solid tumors/diffuse large B-cell lymphoma; initial Phase 1 data on BMS-986249 and Opdivo in solid tumors or lymphomas
  • Corvus Pharmaceuticals Inc (NASDAQ: CRVS): initial Phase 1b/2 data for CPI-444 in solid tumors
  • Pfizer Inc. (NYSE: PFE): Presentation of data on Bavencio in bladder cancer
  • CELYAD SA/ADR (NASDAQ: CYAD): Phase 1 data on CYAD-101 in colorectal cancer
  • Immunomedics, Inc. (NASDAQ: IMMU): Phase 2 data on sacituzumab govitecan in urothelial cancer
  • Xencor Inc (NASDAQ: XNCR): initial Phase 1 data on XmAb20717 in solid tumors
  • MacroGenics Inc (NASDAQ: MGNX): Phase 1 data on MGD013 in solid tumors; Phase 1/2 data for MGC018 in solid tumors
  • DelMar Pharmaceuticals Inc (NASDAQ: DMPI): Phase 2 data on VAL-083 in unmethylated newly diagnosed glioblastoma multiforme
  • Salarius Pharmaceuticals Inc (NASDAQ: SLRX): Phase 1 data on seclidemstat in Ewing sarcoma
  • AstraZeneca: Phase 3 data on Tagrisso in non-small cell lung carcinoma
  • Genocea Biosciences Inc (NASDAQ: GNCA): updated Phase 1/2 data on GEN-009 vaccine for various cancers
  • NextCure Inc (NASDAQ: NXTC): Phase 1 biomarker data on NC318 in solid tumors
  • Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH): Phase 1 data on SB 11285 in solid tumors
  • Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP): Summary of Phase 1 data on MAGE-A4 in solid tumors
  • ZIOPHARM Oncology Inc. (NASDAQ: ZIOP): initial Phase 2 data on Ad-RTS-hIL-12, along with veledimex and Libtayo in refractory glioblastoma multiforme
  • Agios Pharmaceuticals Inc (NASDAQ: AGIO): Phase 1 data on vorasidenib in IDHm low-grade glioma
  • Oncternal Therapeutics Inc (NASDAQ: ONCT): updated Phase 1/2 data on cirmtuzumab and ibrutinib in chronic lymphocytic leukemia and mantle cell lymphoma
  • Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY): Phase 2 data on tiragolumab and atezolizumab in non-small cell lung cancer
  • Aptose Biosciences Inc (NASDAQ: APTO): Phase 1 data on CG-806 in chronic lymphocytic leukemia or non-Hodgkin lymphomas
  • Kura Oncology Inc (NASDAQ: KURA): Phase 2 mature data on tipifarnib in head and neck squamous cell carcinomas with HRAS Mutations
  • Innate Pharma SA (NASDAQ: IPHA): Phase 2 second cohort expansion data on monalizumab in combination with cetuximab in squamous cell carcinoma of the head and neck
  • Imv Inc (NASDAQ: IMV):: updated Phase 1b data on DPX-Survivac and epacadostat in ovarian cancer
  • MEI Pharma Inc (NASDAQ: MEIP): updated Phase 1b data on ME-401 in relapsed/refractory follicular lymphoma/chronic lymphocytic leukemia
  • TapImmune Inc. common stock (NASDAQ: MRKR): updated Phase 1/2 data on MultiTAA-Specific T Cells in pancreatic cancer
  • Inovio Pharmaceuticals Inc (NASDAQ: INO):: Phase 1/2 12-month overall survival data on INO-5401 in glioblastoma

ISCT Presentations

Mesoblast limited (NASDAQ: MESO): oral presentation of results using its allogeneic mesenchymal stem cell product candidate remestemcel-L in patients with inflammatory lung disease

ASCP Presentations

Karuna Therapeutics Inc (NASDAQ: KRTX) will present additional data from the Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia.



  • REDHILL BIOPHAR/S ADR (NASDAQ: RDHL) (before the market open)
  • Trinity Biotech plc (NASDAQ: TRIB) (before the market open)


  • Adverum Biotechnologies Inc (NASDAQ: ADVM) (after the close)
  • Geron Corporation (NASDAQ: GERN) (after the close)

IPO Quiet Period Expiry

Lyra Therapeutics Inc (NASDAQ: LYRA)

Correction: Clovis Oncology Inc's (NASDAQ: CLVS) Phase 1b/2 data on the Opdivo-lucitanib combo is due at a medical meeting in fall of 2020.


Related Articles (AZN + MRK)

View Comments and Join the Discussion!

Posted-In: Biotech News Penny Stocks Health Care Previews FDA Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at